EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic significance of C-reactive protein (CRP) and albumin-based biomarker in patients with breast cancer receiving chemotherapy

Prognostische Bedeutung von C-reaktivem Protein (CRP) und albuminbasiertem Biomarker bei Patient:innen mit Brustkrebs unter Chemotherapie

Susanna Hilda Hutajulu, Yufi Kartika Astari, Meita Ucche, Nyoman Kertia, Yanri Wijayanti Subronto, Dewi Kartikawati Paramita, Lina Choridah, Ericko Ekaputra, Irianiwati Widodo, Suwardjo Suwardjo, Mardiah Suci Hardianti, Kartika Widayati Taroeno-Hariadi und 2 weitere

PeerJ · 21.05.2025 · 13 · e19319

DOI: 10.7717/peerj.19319 ↗

Auf einen Blick

Bei 202 Patient:innen mit Brustkrebs war ein hoher CRP-zu-Albumin-Quotient (CAR) mit ungünstigerem krankheitsfreiem und Gesamtüberleben verbunden. Für das progressionsfreie Überleben zeigte sich kein Zusammenhang.

Fragestellung

Welche prognostische Bedeutung hat der CRP-zu-Albumin-Quotient (CAR) bei Patient:innen mit Brustkrebs unter Erstlinien-Chemotherapie?

Methode

202 Patient:innen mit Stadium I–IV und Erstlinien-Chemotherapie; CAR und weitere Biomarker vor Behandlungsbeginn; Analyse mit Kaplan-Meier, Log-Rank-Test und Cox-Regression für DFS, PFS und OS.

Ergebnisse

Medianes Follow-up 46 Monate (1–77). Hoher CAR (>1,5) vs. niedriger CAR (≤1,5): 3-Jahres-DFS 47,0 % vs. 68,9 %; 3-Jahres-OS 59,5 % vs. 78,6 %. Multivariat: DFS HR 2,10 (95 %-KI 1,10–3,99), OS HR 2,16 (95 %-KI 1,27–3,68), PFS HR 1,43 (95 %-KI 0,73–2,80).

Schlussfolgerung der Autor:innen

Neben Alter, Stadium und molekularen Subtypen war CAR ein vielversprechender prognostischer Marker. Ein hoher CAR bei Diagnose war mit ungünstigerem DFS und OS verbunden.

Kernaussagen

  • Hoher CAR (>1,5) war mit schlechterem DFS und OS assoziiert.
  • DFS: HR 2,10 (95 %-KI 1,10–3,99); OS: HR 2,16 (95 %-KI 1,27–3,68).
  • Kein signifikanter Zusammenhang mit PFS (HR 1,43; 95 %-KI 0,73–2,80).

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, online erschienen am 21.05.2025. Verfasst von Susanna Hilda Hutajulu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada…. Hauptthemen laut MEDLINE: Breast Neoplasms, C-Reactive Protein, Biomarkers, Tumor, Serum Albumin. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academic Excellence grant from Universitas Gadjah Mada.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer patients with similar clinicopathologic characteristics may experience varied outcomes. This urges an increased effort to investigate other prognostic factors. C-reactive protein (CRP)-to-albumin ratio (CAR) is an inflammatory and nutritional biomarker that has been well studied and reported to have an impact on the survival of patients with diverse types of cancer, but limitedly in breast cancer. Therefore, this study aimed to investigate the prognostic significance of CAR in local patients with breast cancer.

Methods

This study included 202 stage I–IV breast cancer patients receiving first-line chemotherapy. We calculated inflammatory and nutritional biomarkers including CAR, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), pan-immune-inflammation value (PIV), and prognostic nutrition index (PNI) before treatment. The Kaplan-Meier with log-rank test and Cox proportional hazard regression were used to analyze the prognostic role of clinicopathologic factors and biomarkers on disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS).

Results

The median follow-up period was 46 months (1–77 months). The 3-year DFS and 3-year OS in patients with high CAR (CAR > 1.5) were significantly lower than those with low CAR (CAR ≤ 1.5) (47.0% vs 68.9%, P = 0.022 and 59.5% vs 78.6%, P = 0.009, respectively). Multivariate analysis showed high CAR as prognostic factors for poor DFS (HR 2.10, 95% confidence interval/CI [1.10–3.99], P = 0.023) and OS (HR 2.16, 95% CI [1.27–3.68], P = 0.005), but not for PFS (HR 1.43, 95% CI [0.73–2.80], P = 0.293). In addition, more advanced stage and HER2 positive were correlated with unfavorable DFS and OS, older age predicted poor DFS, and stage was the only prognostic factor of PFS (all P values < 0.05).

Conclusion

Besides age, stage, and molecular subtypes that have been widely observed to have impact on the survival of breast cancer patients, CAR was demonstrated as a promising prognostic marker in our local patients. A high CAR at diagnosis was associated with unfavorable DFS and OS, which can aid in identifying patients at risk and guide personalized treatment planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsC-Reactive ProteinBiomarkers, TumorSerum AlbuminHumansFemaleMiddle AgedPrognosisAdultAgedRetrospective StudiesBiomarkers

Stichwörter der Autor:innen

AlbuminBreast neoplasmsC-reactive proteinMortalitySurvival

Substanzen

C-Reactive ProteinBiomarkers, TumorSerum AlbuminBiomarkers

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Sleman, Yogyakarta Special Region, Ind…
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital, Sleman, Yogyakarta Special Region, Indonesia.
  • Study Program of Subspecialty, Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Sleman,…
  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Sleman, Yogyakarta Special Region, Indonesia.
  • Division of Tropical Medicine and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Sleman, Yogyakarta Special R…
  • Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sleman, Yogyakarta Special Region, Indonesia.

Förderung

  • Academic Excellence grant from Universitas Gadjah Mada

Zitieren

APA

Hutajulu, S. H., Astari, Y. K., Ucche, M., Kertia, N., Subronto, Y. W., Paramita, D. K., Choridah, L., Ekaputra, E., Widodo, I., Suwardjo, S., Hardianti, M. S., Taroeno-Hariadi, K. W., Purwanto, I., & Kurnianda, J. (2025). Prognostic significance of C-reactive protein (CRP) and albumin-based biomarker in patients with breast cancer receiving chemotherapy. PeerJ, 13, e19319. https://doi.org/10.7717/peerj.19319

Vancouver

Hutajulu SH, Astari YK, Ucche M, Kertia N, Subronto YW, Paramita DK, et al. Prognostic significance of C-reactive protein (CRP) and albumin-based biomarker in patients with breast cancer receiving chemotherapy. PeerJ. 2025;13:e19319. doi:10.7717/peerj.19319

BibTeX
@article{Hutajulu2025,
  author = {Hutajulu, Susanna Hilda and Astari, Yufi Kartika and Ucche, Meita and Kertia, Nyoman and Subronto, Yanri Wijayanti and Paramita, Dewi Kartikawati and Choridah, Lina and Ekaputra, Ericko and Widodo, Irianiwati and Suwardjo, Suwardjo and Hardianti, Mardiah Suci and Taroeno-Hariadi, Kartika Widayati and Purwanto, Ibnu and Kurnianda, Johan},
  title = {Prognostic significance of C-reactive protein (CRP) and albumin-based biomarker in patients with breast cancer receiving chemotherapy},
  journal = {PeerJ},
  year = {2025},
  volume = {13},
  pages = {e19319},
  doi = {10.7717/peerj.19319}
}
Kostenlos starten →